Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Phytother Res ; 35(3): 1646-1657, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33155722

ABSTRACT

Recently, several countries authorized the use of cannabis flowering tops (dried inflorescences) with a standardized amount of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD) and their acidic precursors [Δ-9-tetrahydrocannabinolic acid A (THCA-A) and cannabidiolic acid (CBDA)] to treat neurogenic pain. We studied the acute pharmacological effects and disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine of 13 healthy individuals treated with medical cannabis decoction and oil. Cannabinoids and their metabolites were quantified by ultrahigh performance tandem mass spectrometry. Even if the oil contained a significantly higher amount of THC, the absorption of THC and its metabolites were similar in both herbal preparations. Conversely, whereas oil contained a significantly higher amount of CBD and a lower amount of CBDA, absorption was significantly higher after decoction intake. Only cannabinoids present in both herbal preparations (THC, CBD, THCA-A and CBDA) were found in oral fluid, due to the higher acidity compared with that of serum. THC metabolites urinary excretion was always higher after decoction administration. Decoction induced greater feeling of hunger and drowsiness than oil preparation. Pharmacokinetics of cannabinoids, their precursors and their metabolites in biological fluids of individuals treated with cannabis decoction and oil showed a high interindividual variability. The aqueous preparation was generally better absorbed than the oil, even if it contained a minor amount of THC, THCA-A and CBD.


Subject(s)
Cannabinoids/therapeutic use , Cannabis/chemistry , Medical Marijuana , Pharmaceutical Preparations/chemistry , Sweat/chemistry , Adult , Cannabinoids/pharmacology , Female , Humans , Male , Medical Marijuana/blood , Medical Marijuana/pharmacology , Medical Marijuana/therapeutic use , Medical Marijuana/urine , Plant Extracts/blood , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Plant Extracts/urine , Young Adult
2.
Drug Alcohol Depend ; 204: 107539, 2019 11 01.
Article in English | MEDLINE | ID: mdl-31585358

ABSTRACT

BACKGROUND: We examined marijuana and alcohol use trends among drivers aged ≥16 years evaluated at Level I trauma centers before and after Arizona legalized medical marijuana in April 2011. METHODS: We conducted interrupted time series (ITS) analysis of urine drug screens for marijuana metabolites and blood alcohol concentration (BAC) data from the 2008-2014 Arizona State Trauma Registry. RESULTS: Among 30,083 injured drivers, 14,710 had marijuana test results, and 2590 were positive for marijuana; of these, 1087 (42%) also tested positive for alcohol. Among 23,186 drivers with BAC results, 5266 exceeded the legal limit for their age. Compared with prelaw trends (models if law had not been enacted), postlaw models showed small but significant annual increases in the proportions of drivers testing positive for either substance. By the end of 2014, the proportion of drivers testing positive for marijuana was 9.6% versus a projected 5.6% if the law had not been enacted, and the proportion of drivers with illegal BACs was 15.7% versus a projected 8.2%. When ITS was restricted to only substance-tested drivers, no significant differences were detected. CONCLUSIONS: Despite the small annual postlaw increases in the proportion of marijuana-positive drivers compared with the prelaw trend, alcohol-impaired driving remains a more prevalent threat to road safety in Arizona.


Subject(s)
Accidents, Traffic/trends , Alcohol Drinking/epidemiology , Automobile Driving , Interrupted Time Series Analysis/methods , Marijuana Use/epidemiology , Trauma Centers/trends , Accidents, Traffic/legislation & jurisprudence , Adolescent , Adult , Aged , Alcohol Drinking/metabolism , Alcohol Drinking/therapy , Arizona/epidemiology , Automobile Driving/legislation & jurisprudence , Blood Alcohol Content , Ethanol/blood , Ethanol/urine , Female , Humans , Male , Marijuana Use/metabolism , Marijuana Use/therapy , Medical Marijuana/blood , Medical Marijuana/urine , Middle Aged , Young Adult
3.
Pediatrics ; 142(6)2018 12.
Article in English | MEDLINE | ID: mdl-30455340

ABSTRACT

BACKGROUND: The impact of secondhand marijuana smoke exposure on children is unknown. New methods allow for the detection of marijuana smoke exposure in children. METHODS: We studied children who were hospitalized in Colorado and had a parent participating in a smoking cessation study; all children had urine samples remaining from the original study as well as consent for future research. Parents completed a survey and urine samples were analyzed for cotinine and marijuana metabolites, including 11-hydroxy-Δ9-tetrahydrocannabinol (COOH-THC), by using liquid chromatography-tandem mass spectrometry. RESULTS: The median age of the children was 6.0 years (range 0-17 years); 57% were boys. Half (55%) were white, 12% were African American, and 33% were of another race; 39% identified as Hispanic. Approximately 46% had detectable COOH-THC, and 11% had detectable THC. Of those with detectable THC, 3 were teenagers, and 6 were <8 years of age. There were no significant differences in urinary COOH-THC concentrations by age, sex, race and/or ethnicity, or socioeconomic status. Children with positive results for COOH-THC were more likely to have parents who use marijuana daily, smoke marijuana versus other forms of use, use daily in the home, and smoke marijuana in another room if the children are around compared with smoking outside. CONCLUSIONS: Approximately half of the children who qualified for our study had biological evidence of exposure to marijuana. Researchers in studies such as this provide valuable data on secondhand exposure to children from parents using tobacco and marijuana and can inform public health policies to reduce harm.


Subject(s)
Hospitalization/trends , Marijuana Smoking/urine , Medical Marijuana/urine , Tobacco Smoke Pollution , Tobacco Smoking/urine , Adolescent , Adult , Biomarkers/urine , Child , Child, Preschool , Colorado/epidemiology , Cotinine/urine , Dronabinol/urine , Female , Humans , Infant , Infant, Newborn , Male , Marijuana Smoking/epidemiology , Smoking Cessation/methods , Substance Abuse Detection/methods , Tobacco Smoke Pollution/analysis , Tobacco Smoking/epidemiology
4.
Drugs R D ; 18(1): 41-44, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29330776

ABSTRACT

BACKGROUND: In many health settings, administration of medicinal cannabis poses significant implementation barriers including drug storage and safety for administering staff and surrounding patients. Different modes of administration also provide different yet potentially significant issues. One route that has become of clinical interest owing to the rapid onset of action and patient control of the inhaled amount (via breath timing and depth) is that of vaporisation of cannabinoid products. Although requiring a registered therapeutic device for administration, this is a relatively safe method of intrapulmonary administration that may be particularly useful for patients with difficulty swallowing, and for those in whom higher concentrations of cannabinoids are needed quickly. A particular concern expressed to researchers undertaking clinical trials in the hospital is that other patients, nurses, and clinical or research staff may be exposed to second-hand vapours in the course of administering vaporised products to patients. OBJECTIVE: The objective of this study was to take samples from two research staff involved in administering vaporised Δ9-tetrahydrocannabinol to participants in a clinical trial, to examine and quantitate cannabinoid presence. METHODS: Blood samples from two research staff were taken during the exposure period for three participants (cannabis users) over the course of approximately 2.5 h and analysed using tandem mass spectrometry. RESULTS: Blood samples taken over a vaporised period revealed exposure below the limit of detection for Δ9-tetrahydrocannabinol and two metabolites, using tandem mass spectrometry analytical methods. CONCLUSIONS: These results are reassuring for hospital and clinical trial practices with staff administering vaporised cannabinoid products, and helpful to ethics committees wishing to quantify risk.


Subject(s)
Cannabinoids/administration & dosage , Health Personnel , Medical Marijuana/administration & dosage , Administration, Inhalation , Cannabinoids/blood , Cannabinoids/metabolism , Cannabinoids/urine , Female , Humans , Medical Marijuana/blood , Medical Marijuana/metabolism , Medical Marijuana/urine , Saliva/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...